Advances in the development of Salmonella-based vaccine strategies for protection against Salmonellosis in humans
JournalJournal of Applied Microbiology
MetadataShow full item record
AbstractSalmonella spp. are important human pathogens globally causing millions of cases of typhoid fever and non-typhoidal salmonellosis annually. There are only a few vaccines licensed for use in humans which all target Salmonella enterica serovar Typhi. Vaccine development is hampered by antigenic diversity between the thousands of serovars capable of causing infection in humans. However, a number of attenuated candidate vaccine strains are currently being developed. As facultative intracellular pathogens with multiple systems for transporting effector proteins to host cells, attenuated Salmonella strains can also serve as ideal tools for the delivery of foreign antigens to create multivalent live carrier vaccines for simultaneous immunization against several unrelated pathogens. Further, the ease with which Salmonella can be genetically modified and the extensive knowledge of the virulence mechanisms of this pathogen means that this bacterium has often served as a model organism to test new approaches. In this review we focus on (1) recent advances in live attenuated Salmonella vaccine development, (2) improvements in expression of foreign antigens in carrier vaccines and (3) adaptation of attenuated strains as sources of purified antigens and vesicles that can be used for subunit and conjugate vaccines or together with attenuated vaccine strains in heterologous prime-boosting immunization strategies. These advances have led to the development of new vaccines against Salmonella which have or will soon be tested in clinical trials. © 2021 The Authors.
Rights/Terms© 2021 The Authors. Journal of Applied Microbiology published by John Wiley & Sons Ltd on behalf of Society for Applied Microbiology.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/15127
- Vi Capsular Polysaccharide Produced by Recombinant <i>Salmonella enterica</i> Serovar Paratyphi A Confers Immunoprotection against Infection by <i>Salmonella enterica</i> Serovar Typhi.
- Authors: Xiong K, Zhu C, Chen Z, Zheng C, Tan Y, Rao X, Cong Y
- Issue date: 2017
- Salmonella enterica as a vaccine carrier.
- Authors: Hegazy WA, Hensel M
- Issue date: 2012 Jan
- Improving Our Understanding of <i>Salmonella enterica</i> Serovar Paratyphi B through the Engineering and Testing of a Live Attenuated Vaccine Strain.
- Authors: Higginson EE, Ramachandran G, Hazen TH, Kania DA, Rasko DA, Pasetti MF, Levine MM, Tennant SM
- Issue date: 2018 Nov 28
- Conversion of RpoS<sup>-</sup> Attenuated <i>Salmonella enterica</i> Serovar Typhi Vaccine Strains to RpoS<sup>+</sup> Improves Their Resistance to Host Defense Barriers.
- Authors: Burda WN, Brenneman KE, Gonzales A, Curtiss R 3rd
- Issue date: 2018 Jan-Feb
- Identification of salmonella pathogenicity island-2 type III secretion system effectors involved in intramacrophage replication of S. enterica serovar typhimurium: implications for rational vaccine design.
- Authors: Figueira R, Watson KG, Holden DW, Helaine S
- Issue date: 2013 Apr 16